Novavax's shares slid 19% after topline data from a new phase 2 trial on its RSV vaccine fail to impress investors.
BiodVax will test its universal flu vaccine candidate M-001 as a standalone shot after it elicited positive immune responses as a primer in a phase 2b trial.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.
U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.
It's summer, when few are thinking about the coming influenza threat. But top vaccine makers are already kicking off their flu shot shipments.
VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.
Hundreds of Takeda employees in R&D and vaccines have relocated from suburban Chicago to the Boston area, according to a new report.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air.
GlaxoSmithKline plans to explore MenB vaccine Bexsero's potential in preventing gonorrhea after a new study suggested plausible protection.